What is Single Cell Technology?
Single Cell Technology specializes in antibody discovery, leveraging its proprietary AbTheneum Antibody Discovery Platform. This innovative technology captures comprehensive data to generate rapidly actionable leads, aiming to overcome traditional hurdles in antibody development by offering enhanced speed, quality, and a broad range of options. The company serves clients facing complex discovery campaigns that require effective and efficient solutions. A dedicated team of scientists and engineers drives their commitment to advancing the field of antibody discovery.
How much funding has Single Cell Technology raised?
Single Cell Technology has raised a total of $5.1M across 2 funding rounds:
Private Equity
$5M
Debt
$91K
Private Equity (2018): $5M with participation from ImmunoPrecise Antibodies Ltd
Debt (2021): $91K led by PPP
Key Investors in Single Cell Technology
ImmunoPrecise Antibodies Ltd
ImmunoPrecise Antibodies Ltd, operating from immunoprecise.com, is likely a strategic partner or investor focused on antibody development and related biotechnologies, given its name and domain.
PPP
Public-Private Partnership
What's next for Single Cell Technology?
The recent influx of substantial expansion capital, as part of its major enterprise-level funding, positions Single Cell Technology for significant scaling and further platform development. This strategic investment is expected to accelerate the company's mission to streamline antibody discovery processes, potentially leading to broader market penetration and the establishment of new industry benchmarks. The company's focus on eliminating traditional obstacles suggests a trajectory towards becoming a key player in providing rapid, high-quality antibody solutions for challenging research and development needs.
See full Single Cell Technology company page
